# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## FORM 8-K

## **CURRENT REPORT**

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): March 22, 2018

United-Guardian, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-10526 (Commission File Number) 11-1719724 (I.R.S. Employer Identification Number)

230 Marcus Boulevard, Hauppauge, New York 11788

(Address of Principal Executive Offices) (Zip Code)

(631) 273-0900

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- [] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- [] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- [] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- [] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. []

#### Item 2.02. Results of Operations and Financial Condition.

On March 22, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated March 22, 2018

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### United-Guardian, Inc.

Date: March 22, 2018

By: <u>/s/ Ken Globus</u> Ken Globus President

## **EXHIBIT 99.1**

## **United-Guardian Reports Higher 2017 Sales & Earnings**

HAUPPAUGE, N.Y., March 22, 2018 (GLOBE NEWSWIRE) -- United-Guardian, Inc., (NASDAQ:UG) reported today that net income for FY-2017 increased by 49% over the previous year, rising from \$2,581,142 (\$0.56 per share) in 2016 to \$3,844,290 (\$0.84 per share) in 2017. Sales for the year were up from \$11,144,462 in 2016 to \$13,434,460 in 2017, an increase of 21%.

Ken Globus, President of United-Guardian, stated, "We had a significant increase in both sales and earnings in 2017, which was the result of both a 40% increase in sales of our cosmetic ingredients and an 18% increase in sales of our most important pharmaceutical product, Renacidin<sup>®</sup> Irrigation. The increase in sales of our cosmetic ingredients was due primarily to renewed sales of one of our Lubrajel<sup>®</sup> products in China, and the increase in Renacidin sales was mainly the result of this being the first full fiscal year of sales of our new single-dose form of that product. We have retained a web consultant to assist us in expanding our marketing efforts for Renacidin via our new Renacidin web site (www.renacidin.com). With some of our new "natural" cosmetic ingredients being actively promoted globally right now, as well as additional "natural" products in varying stages of development, we are optimistic that we will be able to further expand sales of both our cosmetic ingredients and Renacidin as the year progresses."

United-Guardian is a manufacturer of cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products.

Contact: Robert S. Rubinger (631) 273-0900

<u>NOTE</u>: This press release contains both historical and "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements about the company's expectations or beliefs concerning future events, such as financial performance, business prospects, and similar matters, are being made in reliance upon the "safe harbor" provisions of that Act. Such statements are subject to a variety of factors that could cause the company's actual results or performance to differ materially from the anticipated results or performance expressed or implied by such forward-looking statements. For further information about the risks and uncertainties that may affect the company's business please refer to the company's reports and filings with the Securities and Exchange Commission.

## FINANCIAL RESULTS FOR THE YEARS ENDED DECEMBER 31, 2017 AND DECEMBER 31, 2016

#### STATEMENTS OF INCOME

	Years ended December 31,		
	 2017	2016	
Sales:			
Gross Sales	\$ 13,434,460 \$	11,144,462	
Sales allowances and returns	(466,255)	(367,595)	
Net sales	 12,968,205	10,776,867	
Costs and expenses:			
Cost of sales	5,301,352	4,882,644	
Operating expenses	1,785,160	1,852,833	
Research and development	646,079	651,828	
Total costs and expenses	 7,732,591	7,387,305	
Income from operations	 5,235,614	3,389,562	

Investment income	315,165	306,505
Income before provision for income taxes	 5,550,779	 3,696,067
Provision for income taxes	1,706,489	1,114,925
Net income	\$ 3,844,290	\$ 2,581,142
Earnings per common share (basic and diluted)	\$ 0.84	\$ 0.56
Weighted average shares (basic and diluted)	4,594,319	4,594,319

# **BALANCE SHEET DATA**

(condensed)

	December 31,			
		2017		2016
Current assets	\$	11,850,522	\$	13,714,172
Net property, plant, and equipment		942,887		1,090,591
Deferred income taxes (net)				2,382
Other assets (net)		59,471		59,295
Total assets		12,852,880	_	14,866,440
Current liabilities		1,422,383		1,045,951
Deferred income taxes (net)		33,855		
Total Liabilities		1,456,238		1,045,951
Stockholders' equity		11,396,642		13,820,489
Total liabilities and stockholders' equity	\$	12,852,880	\$	14,866,440